CompletedPhase 2

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

United StatesStarted 2001-11-19

Plain-language summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells are rejected by the body's tissues. Peripheral stem cell transplantation with the person's own stem cells followed by donor peripheral stem cell transplantation may prevent this from happening. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy with autologous peripheral stem cell transplantation and donor peripheral stem cell transplantation in treating patients who have multiple myeloma.

Who can participate

Age range

18 Years – 70 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Diagnosis of multiple myeloma meeting 1 of the following criteria: * Bone marrow plasmacytosis with at least 10% plasma cells * Sheets of plasma cells * Biopsy-proven plasmacytoma * Meets at least 1 of the following criteria: * Presence of myeloma (M)-protein in the serum * Presence of M-protein in the urine * Radiographic evidence of osteolytic lesions * Generalized osteoporosis allowed if at least 20% plasma cells in bone marrow * No non-secretory myeloma * Prior M-protein in serum or urine allowed provided patient is now in complete remission * Must be receiving conventional-dose chemotherapy as initial therapy or as salvage therapy * Must have HLA-A, -B, and -DR genotypically identical sibling donor PATIENT CHARACTERISTICS: Age: * 18 to 70 Performance status: * ECOG 0-2 Life expectancy: * Not specified Hematopoietic: * See Disease Characteristics Hepatic: * AST no greater than 3 times upper limit of normal * Bilirubin less than 2.0 mg/dL Renal: * Not specified Cardiovascular: * LVEF greater than 40% at rest if symptomatic cardiac disease is present Pulmonary: * DLCO greater than 50% of predicted (corrected for hemoglobin) if symptomatic pulmonary disease is present Other: * Not pregnant or nursing * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior autologous or allogeneic peripheral blood stem cell or bone marrow transplantation Chemotherapy: *…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

Trial details

NCT IDNCT00014508

SponsorEastern Cooperative Oncology Group

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2007-02

View on ClinicalTrials.gov More Multiple Myeloma and Plasma Cell Neoplasm trials